MYL

Image: Returns Following the Trump Victory

by

To download the table for easier viewing, please select the link . Financials: Trump’s Treasury Secretary choice Steven Mnuchin wants to repeal most of the burdensome Dodd-Frank legislation. A steepening yield curve is helping banks and may drive improved net interest margins in coming periods. Goldman Sachs is ripping higher, leading the Dow’s charge.   Crude Oil: The world is moving to a better balance in supply/demand dynamics in the energy markets. OPEC is talking, has agreed to cuts, and expectations for improved economic growth are helping energy resource pricing. High-beta companies such as Continental Resources are rallying hard.   Energy: Capital spending cuts are bolstering free cash flow in the upstream space as energy resource pricing improves. Reduced regulations could help … Read more

Teva’s ~7x P/E Multiple – Earnings Insight

by

Image Source: Teva Let’s cover some ground on Teva Pharma’s (TEVA) third-quarter report. By Brian Nelson, CFA What management said: “This has been a year of transition for Teva, underscored this quarter by the close of our strategic acquisition of Actavis Generics, which had significant contribution to our results. Actavis will continue to contribute in a meaningful way to the future growth of our generics business through the strengthened R&D capabilities and complementary pipeline and portfolio, and enhance our leadership in an increasingly evolving industry,” stated Erez Vigodman, Teva’s President and CEO. “We were also pleased to report this quarter that we have successfully completed the second pivotal phase three study for SD-809 for tardive dyskinesia and plan to submit … Read more

Pharma, Biotech and How to Consider Investing In It

by

The Valuentum analyst team digs deep into recent trends in big pharma and biotech from the lofty pricing of drugs to political and competitive pressures to ETF considerations and beyond. ~10 mins. If you cannot view the podcast below, please view the transcript below or select the link here. Tickerized for holdings in the XLV and IBB. Brian Nelson, CFA Gilead’s (GILD) hepatitis C regimen, almost a hundred thousand dollars. Vertex’s (VRTX) cystic fibrosis drug — hundreds of thousands of dollars per year. Have the drug companies lost their mind? This is Brian Nelson from Valuentum Securities, and today joining me is Mr. Kris Rosemann and Mr. Chris Araos — and we are going to talk everything healthcare, biotech… Mr. … Read more

Trouble Developing for Generic Pharma Stocks?

by

Image Source: DonkeyHotey Shares of generic pharmaceutical stocks have been punished after news surfaced that the US Justice Department could file charges by year-end following a two year antitrust investigation. By Kris Rosemann Though difficult to say in light of the poor stock performance of generic pharmaceutical makers of late, we continue to be positive on the long-term secular theme of ongoing growth in the availability of low-priced drugs around the globe, a trend that plays favorably into their hands. Yet another regulatory-related blow, however, was dealt to the pharma space November 3, and surprisingly to those exact firms that work tirelessly to reduce the price of more expensive branded drugs, generic pharma. Reports surfaced that the US Justice Department … Read more

Update on Teva and the Generics Market

by

By Kris Rosemann Teva Pharmaceuticals (TEVA) closed its ~$40.5 billion acquisition of Allergan’s (AGN) Generics business Actavis August 3 after a long back and forth with regulators about the assets it was forced to unload. Nevertheless, the deal strengthens Teva’s position in key markets such as the US, Canada, Russia, and the UK while providing a new commercial presence in growth markets, specifically in the Asia-Pacific region. The generic pharma market remains very strong, in our view. The highest growing segment of the global generics market, “Growth Markets” shown in the image below, is expected to grow at a 10% compound annual growth rate (CAGR) in the period from 2015-2020. Over the same time period, the US generics market is … Read more

Recent M&A Activity

by

Amid the recent market volatility, firms have remained active in M&A. Let’s take a closer look at what companies will be joining forces. DENTSPLY and Sirona to Join Forces DENTSPLY (XRAY) and Sirona Dental Systems (SIRO) announced September 15 that they have entered an all-stock merger agreement. The resulting company will be the world’s largest manufacturer of professional dental products and technologies. Under the proposed agreement, Sirona shareholders will receive ~1.8 shares of DENTSPLY for each existing Sirona share. If the transaction receives regulatory and shareholder approval, it is expected to close in the first quarter of 2016, and the combined company expects the merger to be accretive to adjusted earnings per share for both companies’ shareholders in the first … Read more

Best Ideas Newsletter Holding Teva Surges!

by

On July 27, Teva Pharmaceuticals (TEVA) reported solid preliminary results for the second quarter of 2015. The firm is growing organically, and its fundamental strengths shone throughout its report. Revenue increased 6% in the period, after excluding the impact of currency headwinds and the sale of US OTC plants in the second quarter of 2014. Non-GAAP operating income grew 16% from the year-ago quarter to $1.6 billion, and non-GAAP earnings per share increased 15% to $1.43 in the period. Cash flow from operations advanced an impressive 41% to $1.5 billion in the second quarter, and free cash flow grew 51% to $1.3 billion in the period. The solid bottom line performance caused management to raise its earnings per share guidance … Read more

Teva Pharmaceuticals Committed to Acquiring Mylan

by

Image source: Teva July 5 investor presentation We have been adamant on our stance on Best Ideas Newsletter portfolio holding Teva Pharmaceuticals (TEVA) since the initiation of our thesis on the generics industry in June 2013, shortly before we initiated our position in the firm. Since then shares have advanced nearly 50%, and we’ve continued to let this winner run.   A large portion of Teva’s success has been tied to the incredible performance of Copaxone, the leading multiple sclerosis therapy worldwide. In the first quarter of 2015, the drug alone comprised 18.5% of revenue, while contributing an astounding ~55% of net income. These figures are down from the year-ago period–and the majority of its production life–due in part to … Read more

Things for Your Radar Tuesday

by

Hearing that: Windows 10 launch will be at the end of July. Positive for Microsoft (MSFT). Teva Pharma (TEVA) and Mylan (MYL) looking to tie the knot. Teva getting a nice bounce. IBM’s (IBM) top-line still weak. No interest in shares. Big Blue is not the blue chip equity it once was. Legacy Reserves (LGCY) cuts dividend. No surprise here. We’ve been expecting this for some time. Under Armour (UA) is too rich for our taste. Shares are off after first-quarter report. Rio Tinto (RIO) sees sharp drop in first-quarter iron ore shipments. We’re not interested in adding. ITW (ITW) suffering from guidance cut. Industrial bellwether supporting case that the industrial economy is slowing a tad. Hasbro (HAS) has a … Read more

Mylan’s Deal for Perrigo Boosts Teva

by

Image Source: epSos .de We outlined the case on Best Ideas portfolio holding Teva (TEVA) in our generics industry thesis here. The company was added to the portfolio July 24, 2013 at $41.22 per share. Teva Pharma’s shares are now trading north of $66 each, converging to our fair value estimate in just less than two years. With valuations stretched throughout much of our coverage universe, we’re going to continue to let this winner run. Driving the firm higher April 8 was news of Mylan’s (MYL) bid for Perrigo (PRGO) at a significant premium to the latter’s share price. Under the conditions of the non-binding proposal, Perrigo shareholders would receive $205 in a combination of cash and Mylan stock for … Read more